Keyphrases
Anti-adalimumab Antibodies
100%
Inflammatory Bowel Disease
100%
Adalimumab
100%
Radioimmunoassay
30%
Treatment Failure
20%
Reporter Gene Assay
20%
Methodological Bias
10%
Enzyme-linked Immunosorbent Assay (ELISA)
10%
Short-term Treatment
10%
Temporal Features
10%
Negative Samples
10%
Non-persistent
10%
Limit of Detection
10%
Drug Efficacy
10%
Drug Failure
10%
Odds Ratio
10%
Serum Samples
10%
Treatment Duration
10%
Clinical Observation
10%
Pharmacologically Active
10%
Antibody-associated
10%
Disease Course
10%
Clinical Significance
10%
Loss of Response
10%
Medicine and Dentistry
Patient with Inflammatory Bowel Disease
100%
Adalimumab
100%
Radioimmunoassay
15%
Reporter Gene
10%
Enzyme Immunoassay
5%
Odds Ratio
5%
Clinical Observation
5%
Clinical Significance
5%
False Negative Result
5%
Treatment Duration
5%
Cohort Analysis
5%
Disease Course
5%
Drug Efficacy
5%
Inflammatory Bowel Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
100%
Inflammatory Bowel Disease
100%
Radioimmunoassay
15%
Enzyme Immunoassay
5%
Disease Course
5%
Cohort Study
5%
Elimination
5%
Neuroscience
Adalimumab
100%
Inflammatory Bowel Disease
100%
Radioimmunoassay
15%
Reporter Gene
10%
Immunoassay
5%
Veterinary Science and Veterinary Medicine
Radioimmunoassay
100%
Clinical Significance
33%